Friday, October 17, 2025

Biocon Biologics And Civica Expand Partner And Launch Private-Label Insulin Glargine To Broaden U.S. Diabetes Treatment Options

Additional treatment options for the 38.4 million U.S. patients living with diabetes

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced expansion of its strategic collaboration with Civica, Inc. (Civica) to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins.

The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialize under Biocon Biologics’ existing marketing approval (a private label agreement). Civica will distribute, promote, and sell the medicine in the United States under a separate Civica label and trade dress, and in California, the product will carry the CalRx brand. Biocon Biologics will continue to directly commercialize Biocon Biologics’ own Insulin Glargine-yfgn medicine, which was approved by the U.S. Food and Drug Administration (FDA) in July 2021 as the first interchangeable biosimilar.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: "Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the U.S. and globally. By extending our collaboration with Civica, Inc. to include Insulin Glargine, we are building on our differentiated approach to serving and enhancing patient access—by retaining our direct commercialization and through this strategic partnership. This collaboration enables us to reach underserved populations through new channels in direct alignment with our mission.”

No technology transfer is involved in the agreement and Biocon Biologics will continue to own the intellectual property and marketing authorization associated with Insulin Glargine. Additional terms of the agreement are not disclosed.

This agreement expands the relationship between the two organizations that previously announced that Biocon Biologics will provide Civica with Insulin Aspart drug substance to manufacture in the United States.

Ned McCoy, President and Chief Executive Officer, Civica, Inc., said: “We are pleased to expand our partnership with Biocon Biologics, which helps us achieve a significant milestone in our insulin initiative. Today’s announcement allows us to realize our goal of bringing insulin to people who need it at a transparent low price."

Insulin glargine-yfgn injection is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of use: Insulin glargine-yfgn is not recommended for the treatment of diabetic ketoacidosis.

There are 38.4 million people with diabetes in the United States, approximately 11.6 percent of the total population, with nearly a quarter being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic.1

Biocon Biologics is a global leader in biosimilars and insulin production and is the fourth largest insulins company in the world, providing over 9.2 billion doses of insulin globally with a broad portfolio comprising basal, mixed and rapid acting insulins.

Important Safety Information:

Insulin Glargine-yfgn is contraindicated

·         during episodes of hypoglycemia and in patients with hypersensitivity to insulin glargine products or any of the excipients in Insulin Glargine-yfgn.

Warnings and Precautions:

·         Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.

·         Monitor blood glucose in all patients treated with insulin. Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring.

·         Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate the injection site to unaffected areas and closely monitor for hypoglycemia.

·         Hypoglycemia is the most common adverse reaction associated with insulins, including insulin glargine products. Severe hypoglycemia can cause seizures, may be life threatening, or cause death. Hypoglycemia can impair concentration and reaction time.

·         Accidental mix-ups between insulin products have been reported. To avoid medication errors between Insulin Glargine-yfgn and other insulins, instruct patients to always check the insulin label before each injection.

·         Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Insulin Glargine-yfgn, treat and monitor until symptoms and signs resolve.

·         All insulin products, including Insulin Glargine-yfgn, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia, if indicated.

·         Fluid retention, which may lead to or exacerbate heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure develops, dosage reduction or discontinuation of the TZD must be considered.

·         Do not dilute or mix Insulin Glargine-yfgn with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Insulin Glargine-yfgn via an insulin pump or intravenously because hypoglycemia can occur.

·         A reduction in the Insulin Glargine-yfgn dose may be required in patients with renal or hepatic impairment.

Refer to full Prescribing Information for insulin glargine-yfgn injection for more information.

1 U.S. Department of Health & Human Services, Centers for Disease Control and Prevention. “National Diabetes Statistics Report.” Accessed: January 28, 2025. Last Reviewed: May 15, 2024. https://www.cdc.gov/diabetes/php/data-research/index.html

About Biocon Biologics Limited: 

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve over 6.0 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). The meaningful progress on ESG parameters has been recognized with the Company's inclusion in the S&P Global Sustainability Yearbook in 2025. Website: www.bioconbiologics.com; Follow us on  X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates.

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.  

Website: www.biocon.com; Follow-us on X (formerly Twitter) @bioconlimited and LinkedIn: Biocon for company updates.

About Civica, Inc.: 

Civica is a non-profit generic pharmaceutical company established in 2018 to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.  Civica has built a sterile injectable manufacturing plant in Petersburg, Virginia capable of producing prefilled pens and vials of insulin.

Website:  www.civicarx.org  Follow us on X (formerly Twitter) @civicarx and LinkedIn:  CivicaRx for company updates.

Dalmia Bharat Reported Consolidated Financial Results For Quarter & Half Year Ended September 30, 2025

 Delivering Profitable Growth

Q2 FY26 Highlights

  • Sales Volume stood at 6.9 MnT

  • Quarterly EBITDA grew 60% to Rs 696 Cr

  • EBITDA/T increased by 56% YoY to Rs 1,013/T

  • Net Debt to EBITDA stood at 0.56x as on Sept 30, 2025

  • Commenced Trial Run production of 3.6 MnT clinker line at Umrangso, Assam

  • Share of Renewable Power Consumption stood at 48.1%

(Operational RE capacity including Group Captive - 387MW)

Dalmia Bharat Limited, (BSE: 542216, NSE: DALBHARAT), a leading cement manufacturing company, reported its consolidated financial results for the quarter and half year ended September 30, 2025. 

Financial Highlights for the Quarter and Half year ended September 30, 2025

(Figures in Rs. Crores)

Particulars

Q2FY26

Q2FY25

YoY

H1FY26

H1FY25

YoY

Sales Volume (MnT)

6.9

6.7

2.9%

13.9

14.1

(1.7%)

Income from Operations

3,417

3,087

10.7%

7,053

6,708

5.1%

EBITDA

696

434

60.3%

1,579

1,103

43.1%

EBITDA/T (Rs/T)

1,013

650

55.9%

1,138

782

45.6%

PAT^

239

49

387.8%

634

194

226.8%

Net Debt to EBITDA (x)

0.56x

0.25x

0.3x

0.56x

0.25x

0.3x


^Note: Exceptional Items in H1FY25 includes impact of Rs 113 Cr (Pre-Tax) on account of one-time provision being created with Jaiprakash Associates Ltd. undergoing Insolvency Proceedings, which was later reduced by Rs 16 Cr in Q1 FY26 after review of position

Commenting on the performance, Mr. Puneet Dalmia, Managing Director & CEO – Dalmia Bharat Limited, said, “GST rate cut is a commendable initiative by the Indian government aimed at boosting consumption and demand at a time when the economy is navigating through external geopolitical pressures. Reduction in GST on cement from 28% to 18% is a long-awaited fiscal relief and a welcome step.” He further added, “At Dalmia Bharat, we remain focused upon building scale and delivering profitable growth, and I am confident that we are well positioned to capture the tremendous opportunities that lie ahead of us.”

Mr. Dharmender Tuteja, Chief Financial Officer – Dalmia Bharat Limited, said “During the quarter, our revenues improved by 11% YoY while EBITDA increased by 60% to Rs 696 Cr backed by healthy cement realizations and benign costs. Our 3.6 MnT Umrangso clinker line has commenced trial production in Sep’2025 and should commence commercial production by Q3 FY26. With a strong balance sheet and encouraging profitability outlook, we are steadily progressing towards our vision of becoming a PAN-India player.”

Key updates

  • Trial runs commenced at the 3.6 MnT clinker line in Umrangso, Assam during September, with commercial production expected to begin in Q3 FY26.

  • Commissioned 93 MW of RE capacity, taking our operational RE capacity to 387 MW

  • In line with the Capital Allocation framework, the company has declared an interim dividend of Rs 4 per share.

Key Recognitions during the quarter

Dalmia Cement has been conferred with several prestigious national awards, reinforcing its commitment to operational excellence, sustainable practices, workplace safety, and environmental stewardship.

  • Excellence in Energy Management
    Dalmiapuram, Ariyalur, Rajgangpur, Kapilas Cement Works, Rohtas Cement Works, and Lanka Cement Works were recognized for outstanding energy performance. In addition, Ariyalur Cement, Dalmiapuram Unit and Lanka Cement Works were distinguished as National Energy Leaders, reflecting our leadership in energy efficiency.

  • Architectural Aesthetics
    Shuttle by Dalmia Bharat won 4th CECR Award by CECR magazine for its innovation and excellence in architectural design, highlighting the company’s contribution to advancing building aesthetics.

  • Environmental Leadership
    The Dalmiapuram Kalaikudi Mines received the National Environment Award 2024–25 from the Federation of Indian Mineral Industries for exemplary initiatives in sustainable mining and environmental protection.

These recognitions collectively underscore Dalmia Cement’s unwavering focus on sustainability, innovation, safety, and the well-being of its workforce, while setting new benchmarks for the industry.

7 Eco-Friendly Getaways For The Diwali Long Weekend With NueGo

This Diwali, swap the fireworks for a silent, safe, and sustainable road trip with NueGo — India’s largest intercity electric AC bus brand.

The Diwali long weekend is here, and travel enthusiasts across India are ready to escape the city buzz for a quick festive recharge. This year, go beyond the usual and make your journey part of the celebration — by choosing a cleaner, greener, and quieter way to travel.

 

NueGo, India’s largest intercity electric AC bus brand with a fleet of 300+ electric buses across 120+ cities, is redefining festive travel through its silent, safe, and sustainable journeys. Whether you’re heading home, seeking a spiritual escape, or chasing scenic calm, NueGo ensures your trip is as refreshing as your destination.

 

Here are 7 eco-conscious getaways you can plan this Diwali long weekend:

  1. Delhi → Jaipur

Soak in royal architecture, festive lights, and Rajasthani hospitality. The Pink City awaits — and NueGo’s quiet, comfortable electric ride makes getting there half the joy.

 

How to Get There with NueGo:

Daily electric AC buses between Delhi and Jaipur, with fares starting at just ₹299, ensure a comfortable, safe, and sustainable journey.

  1. Delhi → Dehradun

Escape into the serenity of the Doon Valley, surrounded by hills and fresh air — a perfect way to trade crackers for calm.

 

How to Get There with NueGo:

Daily electric AC buses between Delhi and Dehradun, with fares starting at just ₹269, offer a smooth and peaceful electric ride through scenic landscapes.

  1. Bangalore → Tirupati

Seek divine blessings sustainably! The tranquil Tirumala hills are best visited through a silent, emission-free journey.

How to Get There with NueGo:

Daily electric AC buses connect Bangalore with Tirupati, with fares starting at just ₹539, ensuring a safe and comfortable journey for pilgrims.

  1. Bangalore → Coimbatore

From waterfalls to forest trails, Coimbatore is a nature lover’s paradise — and this festive season, you can reach it sustainably.

How to Get There with NueGo:

Daily electric AC buses connect Bangalore with Coimbatore, with fares starting at ₹450, ensuring a comfortable and eco-friendly intercity journey.

  1. Hyderabad → Vijayawada

Reconnect with your roots or explore Andhra’s cultural heart — a short and sustainable getaway for the festive weekend.

How to Get There with NueGo:

Daily electric AC buses connect Hyderabad with Vijayawada, with fares starting at ₹314, ensuring a smooth, silent, and safe ride

  1. Chennai → Pondicherry

Breathe in the coastal air and French vibes of Pondicherry — the perfect festive retreat just a few hours away.

How to Get There with NueGo:

Daily electric AC buses connect Chennai with Pondicherry, with fares starting at ₹297, ensuring a clean, silent, and scenic ride along the coast.

  1. Indore → Bhopal

Experience central India’s festive warmth and architectural charm — a short and green weekend escape.

How to Get There with NueGo:

Daily electric AC buses between Indore and Bhopal, with fares starting at ₹292, ensure a quick, safe, and sustainable journey.

Festive Offer

To make your festive travel even more joyful, NueGo is offering an exclusive 10% discount for all customers who use the code FESTIVE when booking through the NueGo app or website www.nuego.in.

 

This Diwali, skip pollution and travel responsibly. Let your journey reflect the true spirit of the festival — bright, clean, and full of joy.

 

#TravelGreenWithNueGo #SilentSafeSustainable

 

NueGo buses are 100% eco-friendly, providing zero tailpipe emissions, noiseless rides, reclining seats, CCTV surveillance, live tracking, mobile charging points, and ample legroom — ensuring your spiritual journey is as comfortable as it is sustainable.

NIIF’s India-Japan Fund invests INR 500 Cr In EKA Mobility To Accelerate India’s Transition To Sustainable Transportation


India-Japan Fund (“IJF”), a fund managed by National Investment and Infrastructure Fund Limited (“NIIF”), announces an investment of INR 500 cr (US$ 57 mn) in EKA Mobility, a leading electric vehicle manufacturer focusing on commercial vehicles.

This aligns with IJF’s objective to invest in the climate segment and further accelerate investments in the India-Japan corridor.

EKA Mobility, a subsidiary of Pinnacle Industries, has one of the widest ranges of electric commercial vehicles developed with in-house R&D and technological capabilities, ably supported by indigenous software and engineering capabilities.

The capital infusion from IJF is expected to support EKA Mobility's plans to increase its manufacturing capacity, advance research and development initiatives, improve its supply chain infrastructure, and enhance its marketing efforts aimed at domestic and international markets.

EKA Mobility's existing shareholders include VDL Groep (Netherlands), Mitsui & Co., Ltd. (Japan), and ENAM Holdings (India).

Krishna Kumar, Partner & Fund Head-IJF, said, “Our investment in EKA Mobility continues to reflect our confidence in India’s electric mobility potential and the capability of homegrown OEMs to drive meaningful change in the market. IJF is supporting enterprises that are shaping India’s journey to a low-carbon economy, and also committed to promoting India-Japan business partnerships. We are glad to support Eka Mobility's growth in the sustainable commercial transportation segment, wherein it combines its technical, design capabilities and manufacturing infrastructure to take advantage of India's transition in the mobility segment.”

Makoto Uchida, Senior Managing Director at Japan Bank for International Cooperation (JBIC) and Executive Director at JBIC IG Partners, said, "We welcome IJF's partnership with EKA Mobility, reflecting the fund's commitment to invest in opportunities that contribute to environmental preservation in India as well as to promote collaboration between Indian and Japanese companies. Together with our partner NIIF, JBIC group -including our subsidiary JBIC IG Partners, which is supporting NIIF in promoting Japanese investments in India through the IJF initiative - will continue to contribute to deepening the bilateral relationship between India and Japan."

Dr. Sudhir Mehta, Founder & Chairman of EKA Mobility, added, “We are proud to have NIIF as a strategic partner in our growth journey. This investment comes at a crucial time as we expand operations, strengthen our R&D, and accelerate the adoption of electric mobility across India. NIIF’s support reinforces our shared vision of creating sustainable, inclusive, and future-ready transportation solutions.”

The collaboration between NIIF and EKA Mobility aligns with the Government of India’s stated objectives on electrification of public transport and promotion of domestic manufacturing under the Make-in-India and Atmanirbhar Bharat initiatives.

The company’s portfolio of zero-emission vehicles spans electric buses (7m, 9m, and 12m variants), intercity coaches, 3-wheeler passenger and cargo vehicles, heavy-duty trucks (55T and 7T) and small commercial vehicles in the 1.5T, 2.5T, and 3.5T categories. The company has confirmed orders for over 3,300 electric buses as part of state government procurements, municipal corporation contracts, and private commercial fleets.

Total Pageviews